Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate

Giovanni Gambaro, Norella C T Kong

    Research output: Contribution to journalArticle

    12 Citations (Scopus)

    Abstract

    Patients with primary and secondary chronic glomerular diseases are at significant risk for progression to end-stage renal disease. Unfortunately the treatment armamentarium is relatively limited in terms both of available agents and of specificity. Experimental evidence supports the idea that heparin-derived agents and glycosaminoglycans (GAGs) favorably affect primary and secondary renal diseases. While a number of clinical exploratory studies have addressed the effect of these agents in microalbuminuric and macroalbuminuric diabetic patients, very few have investigated their activity in nondiabetic renal conditions. This paper will review the experimental and clinical evidence on the use of GAGs in renal disease other than diabetic nephropathy, following the reports of experimental findings supporting their use and the possible mechanisms involved: anticoagulant and antiproliferative activity, effect on growth factors (PDGF, FGF2 and TGF-β1), inhibition of heparanase, macrophage renal infiltration and of the renin-angiotensin system, and decrease in proteinuria. Targeting these pathogenic loops with GAG treatment might be revealed to be very rewarding from a clinical point of view. Prospective randomized controlled trials with large case populations and definite entry criteria are clearly indicated.

    Original languageEnglish
    Pages (from-to)244-252
    Number of pages9
    JournalJournal of Nephrology
    Volume23
    Issue number3
    Publication statusPublished - May 2010

    Fingerprint

    Glomerulonephritis
    Glycosaminoglycans
    Kidney
    Diabetic Nephropathies
    Fibroblast Growth Factor 2
    Therapeutics
    Renin-Angiotensin System
    Proteinuria
    Anticoagulants
    Chronic Kidney Failure
    Heparin
    Intercellular Signaling Peptides and Proteins
    Chronic Disease
    Randomized Controlled Trials
    Macrophages
    Population

    Keywords

    • Glomerulonephritis
    • Glycosaminoglycans
    • Heparanase-1
    • Heparin
    • Macrophage
    • Proteinuria
    • TGF-β1

    ASJC Scopus subject areas

    • Nephrology

    Cite this

    Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate. / Gambaro, Giovanni; Kong, Norella C T.

    In: Journal of Nephrology, Vol. 23, No. 3, 05.2010, p. 244-252.

    Research output: Contribution to journalArticle

    Gambaro, Giovanni ; Kong, Norella C T. / Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate. In: Journal of Nephrology. 2010 ; Vol. 23, No. 3. pp. 244-252.
    @article{eefa1bd7c94a420a97e4e02fef0a50f0,
    title = "Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate",
    abstract = "Patients with primary and secondary chronic glomerular diseases are at significant risk for progression to end-stage renal disease. Unfortunately the treatment armamentarium is relatively limited in terms both of available agents and of specificity. Experimental evidence supports the idea that heparin-derived agents and glycosaminoglycans (GAGs) favorably affect primary and secondary renal diseases. While a number of clinical exploratory studies have addressed the effect of these agents in microalbuminuric and macroalbuminuric diabetic patients, very few have investigated their activity in nondiabetic renal conditions. This paper will review the experimental and clinical evidence on the use of GAGs in renal disease other than diabetic nephropathy, following the reports of experimental findings supporting their use and the possible mechanisms involved: anticoagulant and antiproliferative activity, effect on growth factors (PDGF, FGF2 and TGF-β1), inhibition of heparanase, macrophage renal infiltration and of the renin-angiotensin system, and decrease in proteinuria. Targeting these pathogenic loops with GAG treatment might be revealed to be very rewarding from a clinical point of view. Prospective randomized controlled trials with large case populations and definite entry criteria are clearly indicated.",
    keywords = "Glomerulonephritis, Glycosaminoglycans, Heparanase-1, Heparin, Macrophage, Proteinuria, TGF-β1",
    author = "Giovanni Gambaro and Kong, {Norella C T}",
    year = "2010",
    month = "5",
    language = "English",
    volume = "23",
    pages = "244--252",
    journal = "Journal of Nephrology",
    issn = "1121-8428",
    publisher = "Wichtig Publishing",
    number = "3",

    }

    TY - JOUR

    T1 - Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate

    AU - Gambaro, Giovanni

    AU - Kong, Norella C T

    PY - 2010/5

    Y1 - 2010/5

    N2 - Patients with primary and secondary chronic glomerular diseases are at significant risk for progression to end-stage renal disease. Unfortunately the treatment armamentarium is relatively limited in terms both of available agents and of specificity. Experimental evidence supports the idea that heparin-derived agents and glycosaminoglycans (GAGs) favorably affect primary and secondary renal diseases. While a number of clinical exploratory studies have addressed the effect of these agents in microalbuminuric and macroalbuminuric diabetic patients, very few have investigated their activity in nondiabetic renal conditions. This paper will review the experimental and clinical evidence on the use of GAGs in renal disease other than diabetic nephropathy, following the reports of experimental findings supporting their use and the possible mechanisms involved: anticoagulant and antiproliferative activity, effect on growth factors (PDGF, FGF2 and TGF-β1), inhibition of heparanase, macrophage renal infiltration and of the renin-angiotensin system, and decrease in proteinuria. Targeting these pathogenic loops with GAG treatment might be revealed to be very rewarding from a clinical point of view. Prospective randomized controlled trials with large case populations and definite entry criteria are clearly indicated.

    AB - Patients with primary and secondary chronic glomerular diseases are at significant risk for progression to end-stage renal disease. Unfortunately the treatment armamentarium is relatively limited in terms both of available agents and of specificity. Experimental evidence supports the idea that heparin-derived agents and glycosaminoglycans (GAGs) favorably affect primary and secondary renal diseases. While a number of clinical exploratory studies have addressed the effect of these agents in microalbuminuric and macroalbuminuric diabetic patients, very few have investigated their activity in nondiabetic renal conditions. This paper will review the experimental and clinical evidence on the use of GAGs in renal disease other than diabetic nephropathy, following the reports of experimental findings supporting their use and the possible mechanisms involved: anticoagulant and antiproliferative activity, effect on growth factors (PDGF, FGF2 and TGF-β1), inhibition of heparanase, macrophage renal infiltration and of the renin-angiotensin system, and decrease in proteinuria. Targeting these pathogenic loops with GAG treatment might be revealed to be very rewarding from a clinical point of view. Prospective randomized controlled trials with large case populations and definite entry criteria are clearly indicated.

    KW - Glomerulonephritis

    KW - Glycosaminoglycans

    KW - Heparanase-1

    KW - Heparin

    KW - Macrophage

    KW - Proteinuria

    KW - TGF-β1

    UR - http://www.scopus.com/inward/record.url?scp=77951727161&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=77951727161&partnerID=8YFLogxK

    M3 - Article

    C2 - 20155726

    AN - SCOPUS:77951727161

    VL - 23

    SP - 244

    EP - 252

    JO - Journal of Nephrology

    JF - Journal of Nephrology

    SN - 1121-8428

    IS - 3

    ER -